As a key part of our business strategy to disseminate Organoid Technology, HUB offers licences to its proprietary Organoid Technology, know-how and access to the HUB biobank. The licences allow the industry to use our technology. HUB offers the licences and includes tech transfer training to help establish the technology in house. As a drug discovery platform, HUB Organoids can be exploited for target discovery and genomic and functional studies on a scale that cannot be achieved by clinically relevant models. In drug development, HUB Organoids provide drug efficacy, safety, and mechanistic data. Furthermore, disease-specific collections of organoids enable pre-clinical stratification of patient populations.
HUB has created an organoid biobank from patient material that captures disease heterogeneity in diseases such as cancer, cystic fibrosis, COPD and IBD. The biobank is an expanding resource of highly characterised organoids for different organ systems and includes both genetic and clinical data of the patient.
As a key part of our business strategy, HUB offers licences to its proprietary Organoid Technology, know-how and access to the HUB biobank.
Leveraging our expertise in field of Organoid Technology, HUB offers research collaborations based on its state-of-the-art technology platform and extensive experience with innovative technologies. HUB has various collaborations with its partners for developing new organoid models, novel assays, performing mechanism of action studies and generating (proprietary) biobanks in range of different disease areas.
HUB aims to drive innovation through spin-off opportunities as a stand-alone or in combination with other innovative technologies through a variety of commercial structures.